BRIEF published on 12/11/2025 at 23:05, 8 months 14 days ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 8 months 14 days ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 9 months 7 days ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 9 months 7 days ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 9 months 13 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 9 months 13 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 10 months 16 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
PRESS RELEASE published on 10/10/2025 at 15:30, 10 months 16 days ago Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock Xenetic Biosciences, Inc. announces pricing of underwritten stock offering, aiming to raise $4.5 million for immuno-oncology technologies. Canaccord Genuity acts as bookrunner Xenetic Biosciences Stock Offering Immuno-oncology Technologies Canaccord Genuity S-3 Registration Statement
BRIEF published on 08/13/2025 at 14:05, 1 year ago Xenetic Biosciences Reports Q2 2025 Financial Results Financial Results Xenetic Biosciences Q2 2025 DNase I Development Partnership Expansions
PRESS RELEASE published on 08/13/2025 at 14:00, 1 year ago Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q2 2025 results, expands partnership with The Scripps Research Institute for DNase I with CAR T-cell therapies and ends quarter with $4.8M cash Financial Results Xenetic Biosciences DNase I The Scripps Research Institute CAR T-cell Therapies
Published on 08/26/2026 at 15:25, 1 hour 12 minutes ago CF Energy Announces Financial Results for the Three-Month and Six-Month Periods Ended June 30, 2026
Published on 08/26/2026 at 15:00, 1 hour 37 minutes ago Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
Published on 08/26/2026 at 15:00, 1 hour 37 minutes ago Arcus Announces Voting Results of the Annual General and Special Meeting
Published on 08/26/2026 at 14:30, 2 hours 7 minutes ago Klondike Gold Reports Additional Montana Creek Royalty Gold Receipts, Announces Phase 2 2026 Drill Program and Provides Exploration Update
Published on 08/26/2026 at 14:30, 2 hours 7 minutes ago NV Gold Announces Commencement of 2026 Drill Program at its Slumber Gold Project
Published on 08/26/2026 at 16:23, 14 minutes ago Original-Research: Deutsche Rohstoff AG (von First Berlin Equity Research GmbH): Buy
Published on 08/26/2026 at 15:31, 1 hour 5 minutes ago Ground-breaking ceremony for the BVB Health Centre
Published on 08/26/2026 at 15:10, 1 hour 27 minutes ago Gastech 2026 Brings Global Energy Leaders to Bangkok as Asia Drives the Next Wave of Demand
Published on 08/26/2026 at 15:07, 1 hour 29 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 08/25/2026 at 17:45, 22 hours 52 minutes ago CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 08/25/2026 at 17:45, 22 hours 52 minutes ago Imerys-08-2026-information-share-capital-and-voting-rights-as-of-31-July-2026
Published on 08/25/2026 at 08:30, 1 day 8 hours ago Eiffage wins several contracts worth a total of €132 million in the healthcare sector
Published on 08/24/2026 at 18:00, 1 day 22 hours ago Outstanding shares and voting rights statement at 31 July 2026
Published on 08/24/2026 at 17:59, 1 day 22 hours ago Saint-Gobain strengthens its positioning in construction chemicals and light construction in Latin America
